Major Developments: Longqi Technology (09611) will conduct its IPO from January 14 to January 19, planning a global offering of 52.2591 million H shares. Hutchmed (00013) announced that the results of the SACHI Phase III study have been published in *The Lancet*. SUNSHINE PHARMA (06887) has launched an AI-powered R&D platform targeting the PROTAC mechanism, continuously deepening its AI strategic layout. BIODLINK-B (01875) has received a cash offer from WUXI XDC (02268) at a premium of approximately 99% and will resume trading on January 15. LEADS BIOLABS-B (09887): VELIXIN™ (PD-L1/4-1BB bispecific antibody, Opatansu mab, LBL-024) has been granted Fast Track designation by the US FDA. Xunce (03317) has entered into a strategic cooperation framework agreement with Jinyong Investment, aimed at supporting the digital transformation of investment research, trading, and risk management.

Operational Performance: CITIC SEC (06030) reported an attributable net profit of RMB 30.051 billion for 2025, a year-on-year increase of 38.46%. CITIC BANK (00998) reported a net profit attributable to owners of RMB 70.618 billion for 2025, up 2.98% year-on-year. CGN New Energy (01811) achieved a cumulative power generation volume of 19,000 GWh in 2025, a decrease of 0.8% compared to the previous year. Yuexiu Property (00123) reported cumulative contracted sales of approximately RMB 106.21 billion for 2025. WUXI XDC (02268) issued a profit alert, expecting its net profit for 2025 to increase by over 38% year-on-year. BBMG Corporation (02009) issued a profit warning, anticipating an attributable net loss of RMB 0.9 to 1.2 billion for 2025. Solargiga Energy (00580) issued a profit alert, expecting its net profit for 2025 to increase by approximately 30.0% year-on-year. Beijing North Star (00588) issued a profit warning, expecting a net loss attributable to shareholders of RMB 2.696 billion to 3.38 billion for 2025.